Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,808.00
Bid: 6,807.00
Ask: 6,809.00
Change: 14.00 (0.21%)
Spread: 2.00 (0.03%)
Open: 6,779.00
High: 6,873.00
Low: 6,761.00
Yest. Close: 6,794.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

LIVE MARKETS-Closing snapshot: Cashing in

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@...

30 Dec 19 16:50

UPDATE 2-Profit-taking puts brakes on UK stock rally

* FTSE 100 down 0.8%, FTSE 250 down 0.6%* Healthcare firms, oil stocks drag on main index* NMC Health outperforms blue-chips (Adds news items, updates to closing prices)By Shashwat AwasthiDec 30 (Reuters) - British shares fell on the year's penulti...

30 Dec 19 09:16

LIVE MARKETS-STOXX in the red, banks in the black

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@...

30 Dec 19 08:50

AstraZeneca gets US approval for 'Lynparza' in pancreatic cancer

(Sharecast News) - AstraZeneca announced on Monday, alongside its partner MSD, that 'Lynparza', or olaparib, has been approved in the United States for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma, or pancreatic cancer, whose disease had not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

30 Dec 19 08:15

UPDATE 2-AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

* First of its kind to get FDA okay to treat pancreatic cancer* Lynparza belongs to class of treatments called PARP inhibitors* Drug had sales of $847 mln in 9 months to September (Recasts, adds details, executive comment)By Pushkala AripakaDec 30...

30 Dec 19 08:02

TOP NEWS: Astra, Merck & Co's Lynparza Approved For Cancer Treatment

TOP NEWS: Astra, Merck & Co's Lynparza Approved For Cancer Treatment

30 Dec 19 07:54

LONDON MARKET PRE-OPEN: Astra's Lynparza Approved; Rio Restarts RBM

LONDON MARKET PRE-OPEN: Astra's Lynparza Approved; Rio Restarts RBM

30 Dec 19 07:43

LIVE MARKETS-No sparks expected at the open

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@...

30 Dec 19 07:43

AstraZeneca's Triple-Combination Therapy Approved In China

AstraZeneca's Triple-Combination Therapy Approved In China

23 Dec 19 08:12

AstraZeneca upbeat on approvals in China and the US

(Sharecast News) - AstraZeneca announced on Monday that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

23 Dec 19 07:40

US FDA Approves AstraZeneca Breast Cancer Treatment Enhertu

US FDA Approves AstraZeneca Breast Cancer Treatment Enhertu

21 Dec 19 11:51

Friday broker round-up

(Sharecast News) - Segro: HSBC downgrades to hold with a target price of 869p.

20 Dec 19 12:28

LONDON MARKET MIDDAY: Stocks Mixed Ahead Of Johnson's Brexit Deal Vote

LONDON MARKET MIDDAY: Stocks Mixed Ahead Of Johnson's Brexit Deal Vote

20 Dec 19 12:09

LONDON MARKET OPEN: Shell Dips After Warning Over Earnings Hit

LONDON MARKET OPEN: Shell Dips After Warning Over Earnings Hit

20 Dec 19 08:31

AstraZeneca Sells Two Cancer Drug Rights For Up To USD198 Million

AstraZeneca Sells Two Cancer Drug Rights For Up To USD198 Million

20 Dec 19 08:09

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.